We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mirdametinib is an investigational mitogen-activated ...

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin. Basal ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

Please provide your email address to receive an email when new articles are posted on . Severe auditory dysfunction was a common neurobiological feature of neurofibromatosis type 1, according to ...

The FDA has approved selumetinib (Koselugo, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib, an oral kinase ...

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer ...

Learning that your child has neurofibromatosis type 1 (NF1) comes with a range of emotions and practical concerns. While many people diagnosed with NF1 will have a normal life expectancy, the ...

The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically ...

What Is Koselugo, and Why Does It Matter? Koselugo (selumetinib) is an oral medicine that helps slow the growth of certain tumors. The FDA has approved it for adults with neurofibromatosis type 1 (NF1 ...

Inactivating germ line mutations in the neurofibromatosis type 1 (NF1) gene are responsible for the many manifestations of this disease that range from intellectual deficits, to autism, to bone ...